Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 13
Original Research
Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 5,397 | Dovepress* | 4,454+ | 195 | 4,649 | |
| PubMed Central* | 943 | 258 | 1,201 | ||
| Totals | 5,397 | 453 | 5,850 | ||
| *Since 22 October 2021 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 2 | 0 | 0 | 0 | 1 | 1 |
View citations on PubMed Central and Google Scholar